Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
|Articles|October 22, 2021
In case you missed it: Oct. 18 to Oct. 22
Author(s)Lindsey Carr, Editor
It's been a busy week for the Contemporary OB/GYN® team.
Advertisement
Here's what you missed this week:
Diagnosing and treating vaginal discharge
S3E18: Coping with COVID-19
Poll: What content would you like to see more of from Contemporary OB/GYN®?
New risk factors for vulvovaginal candidiasis and recurrence
FDA approves flu vaccine for children as young as 6 months
Advertisement
Related to this article
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
Neurokinin receptor antagonists improve menopausal sleep disturbance
3
Stephanie Faubion, MD, on the first menopause therapy discussion
4
Brain fog at menopause: Separating normal change from dementia
5